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ABSTRACT
Oligonucleotides composed of 20-O-methyl and
locked nucleic acid residues complementary to HIV-1
trans-activation responsive element TAR block
Tat-dependent trans-activation in a HeLa cell
assay when delivered by cationic lipids. We de-
scribe an improved procedure for synthesis and
purification under highly denaturing conditions of
50-disulphide-linked conjugates of 30-fluorescein
labelled oligonucleotides with a range of cell-
penetrating peptides and investigate their abilities
to enter HeLa cells and block trans-activation. Free
uptakeof12merOMe/LNAoligonucleotideconjugates
to Tat (48–58), Penetratin and R9F2 was observed in
cytosolic compartments of HeLa cells. Uptake of the
Tat conjugate was enhanced by N-terminal addition
of four Lys or Arg residues or a second Tat peptide.
None of the conjugates entered the nucleus or in-
hibited trans-activation when freely delivered, but
inhibition was obtained in the presence of cationic
lipids. Nuclear exclusion was seen for free delivery
of Tat (48–58), Penetratin and R9 conjugates of
16mer phosphorothioate OMe oligonucleotide.
Uptake into human fibroblast cytosolic compart-
ments was seen for Tat, Penetratin, R9F2 and
Transportan conjugates. Large enhancements of
HeLa cell uptake into cytosolic compartments were
seenwhenfreeTatpeptidewasaddedtoTatconjugate
of 12mer OMe/LNA oligonucleotide or Penetratin
peptide to Penetratin conjugate of the same
oligonucleotide.
INTRODUCTION
The HIV-1 trans-activation responsive element (TAR) RNA
stem–loop interacts with the HIV trans-activator protein
Tatandothercellularfactorstostimulatetranscriptionalelonga-
tionfromthevirallongterminalrepeat(LTR)(1,2).Inhibitorsof
these interactions would block full-length transcription and
hence the ability of HIV to replicate. Much effort has gone
intovariousapproachestodesignmoleculescapableofbinding
toTARandinhibitingTat-dependenttrans-activationaspoten-
tial candidates for anti-HIV therapies [reviewed in (3)], but so
far no clinical candidates have emerged.
Oligonucleotides and their analogues have been much
studied as potential trans-activation inhibitors because of their
ability to form sequence-speciﬁc interactions with the TAR
RNA target and hence block the ability of Tat and/or cellular
factors to bind. One route involves the design of oligonucleo-
tide aptamers that form kissing complexes with the apical
TAR RNA stem–loop. Various nuclease-stabilized aptamer
analogues have shown promise as trans-activation inhibition
agents in vitro (4–6), but so far these have not led to signiﬁcant
cellular activity. In contrast, an antisense approach against
TAR has yielded encouraging cellular inhibition results in
the case of some oligonucleotide analogues (7,8).
Early studies showed that 18–26mer oligodeoxynucleotide
phosphorothioates, in principle, would allow an RNase H type
of antisense activity, when targeted to the apical stem–loop of
TARinhibitedTat-dependenttrans-activationinatransientcell
assay, but failed to show speciﬁc anti-viral activity (9). Based
on previous studies of the ability of RNA and 20-O-methyl
(OMe) oligoribonucleotides to strand-invade the TAR target
(10), we showed that short steric blocking OMe oligoribo-
nucleotides of 12–16 residues bound TAR RNA strongly and
blockedTat binding very effectively(11,12).SuchOMeoligo-
ribonucleotides were able to inhibit sequence-speciﬁcally Tat-
dependent in vitro transcription directed by HeLa cell nuclear
extract on a DNA template containing the HIV-1 LTR (13).
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observed for other steric block oligonucleotides such as a
mixmer 16mer OMe containing ﬁve 5-methyl C locked
nucleic acid (LNA) units and a 16mer peptide nucleic acid
(PNA) (8).
We utilized a cellular assay involving inhibition of Tat-
dependent HIV LTR trans-activation in a stably integrated
plasmid system in HeLa cells and double luciferase reporters
to show that, when delivered by a cationic lipid, a 12mer
OMe/LNA mixmer oligonucleotide, but not its 12mer OMe
counterpart, had cellular inhibitory activity (8). More recently,
we carried out a detailed structure–function analysis of the
requirements for cellular activity of LNA/OMe mixmer
oligonucleotides with delivery by cationic gemini surfact-
ant/lipid formulation GS11/DOPE (14). This showed
oligomers of 12–16 residues were active, but that a 10mer
was inactive under the assay conditions: 40–50% of LNA
units scattered throughout the OMe oligonucleotide gave
best results and the LNA residues could be placed at different
locations without affecting activity.
Transfection of DNA and negatively charged oligonucleo-
tides and their analogues is usually achieved for common
laboratory cell lines in culture (such as HeLa cells) through
complexation with cationic lipids (15). There is now a wide
choice of such reagents, but there are many difﬁculties in their
use. For example, the oligonucleotide must be formulated with
the delivery reagent and ratios adjusted for each experimental
case to optimize uptake whilst limiting lipid-associated cell
toxicity. Different lipid-based delivery reagents can give rise
to highly variable activity levels, and most formulations are
not suitable for use with primary cells. Further, cationic lipid
formulation has considerable disadvantages for potential
therapeutic use. Accordingly, there has been considerable
motivation to search for alternative methods of oligonucleo-
tide delivery that do not involve lipid complex formation.
Muchrecentinteresthasbeen arousedbythesuggestionthat
certain peptides [known as cell-penetrating peptides (CPP) or
protein transduction domains (PTD)] can translocate into cells
in culture and, when attached covalently, can carry in various
cargoes [reviewed in (16,17)]. Amongst such cargoes are
oligonucleotides and their analogues [reviewed in (18,19)].
Whereas there have been numerous reports showing enhanced
cellular delivery and activity of PNA by covalently attached
CPPs [reviewed in (18)], including a CPP–PNA oligomer
targeted to the TAR RNA (20), the delivery of negatively
charged phosphodiesters or phosphorothioates by CPPs has
been more controversial.
Two early reports showed that a 16-residue cationic peptide
from an Antennapedia homeodomain, called Penetratin, when
covalently linked to phosphodiester oligonucleotides by disul-
phide bond, could enter neuronal cells and down-regulate
different genes (21,22). More recently, disulphide-linked con-
jugates of a 20mer phosphorothioate oligodeoxyribonucleo-
tide with Penetratin or with a second peptide, this time derived
from the arginine-rich domain of the HIV-1 Tat protein, were
found to be taken up by mouse 3T3 cells without additional
carrier and to block expression of P-glycoprotein synthesis
(23). More relevant to steric block applications, Tat or Pene-
tratin peptide conjugates of an 18mer 20-O-methyl phosphoro-
thioate oligonucleotide were shown to be delivered to HeLa
cell nuclei and to exhibit dose-dependent inhibition of splicing
and up-regulate expression of a stably integrated luciferase
gene (24).
In contrast, a number of disulphide-linked conjugates of
phosphorothioate oligonucleotides with a hydrophobic signal
sequence from K-FGF or the same domain extended at the
C-terminus by a nuclear localization signal (NLS) from
transcription factor kB failed to deliver to nuclei of monkey
kidney ﬁbroblast cells CVP-1 and failed to show antisense
activity (25). However, all the conjugates were active when
delivered to the nucleus by cationic lipid.
In preliminary studies, we found that ﬂuorescently labelled,
stable amide conjugates of a 12-long anti-TAR LNA/
OMe mixmer with a 15mer Kaposi-ﬁbroblast growth factor
(K-FGF) peptide or with Transportan-TP10 [a shortened form
of a hybrid of a section of the neuropeptide galanin and the
wasp venom peptide mastoparan (26)] failed to enter HeLa
cells, but were fully active in inhibition of Tat-dependent
trans-activation when delivered by cationic gemini surfactant
(14). It seemed clear therefore that the mere attachment of a
CPP to an oligonucleotide is not itself sufﬁcient to ensure free
cell uptake and biological activity. Apart from the results
of Antopolsky et al. (25), to our knowledge there have been
few systematic attempts to establish the parameters import-
ant for efﬁcient free cell uptake for CPP–oligonucleotide
conjugates.
There are numerous methods reported for synthesis
of peptide–oligonucleotide conjugates [comprehensively
reviewed in (27)]. We have developed previously a number
of methods for such conjugation, e.g. amide bond fragment
condensation on solid support (28,29), native ligation of a
cysteine-containing oligonucleotide with a thioester peptide
(30), 20-aldehyde oligonucleotide conjugations to form thia-
zolidine, oxime and hydrazine linkages (31) and total stepwise
solid-phase synthesis on a single solid support (32). All of
these methods give rise to linkages expected to be stable
within cells. Since the few previously claimed successes for
cell delivery and biological activity of CPP–oligonucleotide
conjugates have all used disulphide linkages between oligo-
nucleotide and peptide moieties (21–24), which are presumed
to have greater lability within cells, it was appropriate there-
fore to prepare disulphide-linked conjugates and investigate
cell activity and delivery.
In this study, we have improved signiﬁcantly the chemical
synthesis and puriﬁcation of disulphide conjugates of CPPs
with ﬂuorescein-labelled oligonucleotides with particular
emphasis on maintaining solubility through use of highly
denaturing conditions. We have investigated HeLa and human
ﬁbroblast cell uptake properties of such conjugates and their
ability to inhibit Tat-dependent trans-activation in our HeLa
cell reporter assay. We show that in many cases attachment of
a CPP does enhance free cell uptake of oligonucleotides, but
that the uptake is conﬁned to cytosolic compartments. The
exclusion from the cell nucleus correlates with the lack of
inhibition of Tat-dependent trans-activation for free delivery
of oligonucleotide–CPP conjugates, suggesting that the barrier
to nuclear activity is due to insufﬁcient release from endo-
somal compartments. We also ﬁnd that uptake is boosted
dramatically by addition of extra free CPP to the conjugate,
pointing to the need for extreme care in synthesis and puri-
ﬁcation of conjugates to avoid overestimation of cell delivery
due to peptide complexation.
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HPLC puriﬁcationswerecarried outusing aWaters HPLC 626
pump and 600S controller attached to a 996 photodiode
array detector. MALDI-TOF mass spectra were recorded on
aVoyager-DEworkstation(PEBiosystems).Matrices usedfor
preparing the MALDI-TOF samples were as follows: (a) a-
cyano-4-hydroxycinnamic acid, 10 mg ml
 1 in acetonitrile–
3% aqueous triﬂuoroacetic acid (TFA) (1:1 v/v) for all
peptides, (b) 2,6-dihydroxyacetophenone, 20 mg ml
 1 and
diammonium hydrogen citrate, 40 mg ml
 1, in 50% aqueous
methanol for phosphodiester oligonucleotide–peptide
conjugates or (c) saturated solution of 2,4,6-trihydroxy-
acetophenone (Aldrich) in 50 mM diammonium hydrogen
citrate/50% acetonitrile (33) for phosphorothioates and
heavily salt-contaminated phosphodiester conjugates. The
accuracy of the mass measurement is regarded as –0.05%.
Peptide synthesis
Peptides were obtained either from Southampton Polypeptides
Ltd or synthesized on an Advanced ChemTech APEX
396 robotic synthesizer (5–10 mmol scale) or a PerSeptive
BiosystemsPioneerpeptidesynthesizer(100mmolscale)using
standard Fmoc/tert-butyl solid phase synthesis techniques.
Arginine was Pbf protected. C-terminal amide peptides
were prepared using NovaSyn TGR resin (Novabiochem),
whereas C-terminal carboxylic acid peptides were synthesized
with the C-terminal amino acid attached to a PEG-PS resin
(PerSeptive Biosystems). Deprotection of all peptides and
cleavage from solid support was achieved by treatment with
TFA in the presence of triethylsilane and water (each 3%).
N-terminal thiol-activated cysteine peptides were synthes-
ized using Boc-L-Cys(Npys)-OH obtained from Bachem.
The only exceptions being CR9-OH and C-Transportan-NH2
which were activated (after synthesis and puriﬁcation) with
2-Aldrithiol (Aldrich) as follows: to a solution of the thiol
peptide (1 mM in 0.1 M NH4HCO3) was added 10 equivalents
of 2-Aldrithiol in DMF (10 mg ml
 1). The solution was mixed
thoroughly and left to stand for 1 h. The peptide was analysed
and puriﬁed using RP–HPLC on a Vydac C8 column (20 ·
250 mm, 10 ml min
 1, buffer A = 1% TFA (aqueous), buffer
B = acetonitrile + 10% buffer A, gradient 5–50% B in 30 min).
All C-terminal cysteine-containing peptides were activated
(if required) and puriﬁed in the same manner.
Named peptide sequences (excluding terminal cysteines)
are Tat (residues 48–58): GRKKRRQRRRP, Penetratin:
RQIKIWFQNRRMKWKKGG, Transportan: GWTLNSA-
GYLLGKINLKALAALAKKIL.
Oligonucleotides
Oligonucleotides were synthesized on a 1 mmol scale accord-
ing to previously reported protocols except that the activator
was changed to 5-ethylthio-1H-tetrazole (a 0.25 M solution in
acetonitrile, Link Technologies). LNA and 20-OMe amidites
were obtained from Link Technologies. The 50-C6 thiol linker
and Beaucage Reagent (to introduce phosphorothioate link-
ages) were purchased from Glen Research. 30-Fluorescein
support for the synthesis of OMe/LNA and OMe/PS oligo-
nucleotides B and C was obtained from Glen Research
[30-(6-Fluorescein)CPG]. The 30-(6-carboxyﬂuorescein) OMe
oligonucleotide A was synthesized as described previously
(34). All other reagents were obtained from Proligo. Oligo-
nucleotides were simultaneously cleaved and deprotected
from the CPG support using saturated aqueous ammonia
solution and were subsequently puriﬁed by ion exchange
HPLC using a DNAPacTM PA-100 (9 · 250) Dionex column
[3mlmin 1,bufferA:25%formamide,1mMNaClO4,20mM
Tris–HCl (pH 6.8), buffer B: 1 mM NaClO4, 20 mM Tris–HCl
(pH 6.8), 400 mM NaClO4], gradient 15–55% B in 20 min.
Products were recovered by dialysis against water followed by
lyophilization. The sequences of the oligonucleotides are
shown in Figure 1.
Preparation of 50-thiol oligonucleotides
The thiol was liberated by reduction of the disulﬁde bond of
the 50-linker of the oligonucleotide [1 mM in a 0.05 M triethyl-
ammonium acetate (TEAA) solution containing 1% triethyl-
amine (TEA)] using aqueous DTT (10 equivalents added from
1 M stock solution). After 1.5 h, the reaction mixture was
desalted using size exclusion chromatography (NAP 10 or
NAP 25 column, Amersham Biosciences) and lyophilized.
The amount of residual DTT impurity was ascertained by
comparing the A260 value for the oligonucleotide with the
amount of thiol present as determined by the Ellman’s test
(measurement at A412, with adjustment to take into account the
absorption at that wavelength of the ﬂuorescein).
Preparation of 50-Pys-activated thiol oligonucleotides
To the 50-thiol oligonucleotide (1 mM in a 0.05 M TEAA
solution) was added a solution of Aldrithiol-2 in DMF
(10 equivalents, 10 mg ml
 1). The reaction mixture was vor-
texedandlefttostandfor1hwhereuponthecrude productwas
puriﬁed by ion exchange HPLC as above.
Conjugations
Route A: Conjugation of activated thiol peptide to thiol
oligonucleotide (conjugates 1–16, 18). General procedure.
To a microfuge tube containing the oligonucleotide (20 nmol
in 50 ml water) formamide (150 ml) and 2 M TEAA buffer
(10 ml) were added. The solution was thoroughly mixed and
the activated peptide was added (80nmol in 8ml). Thesolution
was brieﬂy mixed and allowed to stand for 30 min, whereupon
the conjugate was puriﬁed by HPLC using a 1 ml Resource Q
column (Amersham Biosciences) [1 ml min
 1, buffer A:
20 mM Tris–HCl (pH 6.8), 50% formamide, buffer B: 20 mM
Tris–HCl (pH 6.8), 50% formamide, 400 mM NaClO4],
gradient 0–100% B buffer in 20 min. For highly cationic
peptide conjugates 14, 15, 16 and 18, due to aggregation,
the reaction mixture needed to be treated with extra TEAA
and formamide (order of addition not important) in order to
fully solubilize the product which had precipitated in the
microfuge tube. The product was collected, dialysed and lyo-
philized. The lyophilized product was taken up in the solution
as described in Table 2 for further analysis.
Route B: Conjugation of thiol peptide to activated thiol
oligonucleotide (conjugates 4, 6, 15, 17–19). General
procedure. To a microfuge tube containing the activated oli-
gonucleotide (20 nmol in 50 ml water) formamide (150 ml) and
2 M TEAA buffer (10 ml) were added. The solution was
thoroughly mixed and the thiol peptide was added (50 nmol
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stand for 30 min, whereupon the conjugate was puriﬁed by
HPLC using a 1 ml Resource Q column [1 ml min 1, buffer A:
20 mM Tris–HCl (pH 6.8), 50% formamide, buffer B: 20 mM
Tris–HCl (pH 6.8), 50% formamide, 400 mM NaClO4], gra-
dient 0–100% B buffer in 20 min. For highly cationic peptides
15, 17–19, due to aggregation, the reaction mixture needed to
be treated with extra TEAA and formamide (order of addition
not important) in order to fully solubilize the product which
had precipitated in the microfuge tube. The product was col-
lected, dialysed and lyophilized. The lyophilized product was
taken up in the solution as described in Table 2 for further
analysis. In the case of conjugate 19 (R6-Penetratin-oligo B),
there was considerable precipitation seen during dialysis,
and upon lyophilization, the resultant product could not be
dissolved fully even in 2 M TEAA.
Binding of oligonucleotides and conjugates
to TAR RNA
A polyacrylamide gel mobility shift assaywas used tomeasure
the apparent dissociation constant of oligos or their conjugates
to a 32P-labelled TAR 39mer RNA as previously described
(8,13).
Inhibition of Tat-dependent trans-activation in cells
Inhibition of HIV-1 Tat-mediated transcription trans-
activation by oligonucleotide analogues in HeLa cells was
carried out in a similar way to that described previously
(8,14). Brieﬂy, in each experiment two identical 96-well plates
were prepared with 10 · 10
3 HeLa Tet-Off/Tat/luc-f/luc-R
cells per well and incubated at 37 C for 24 h. One of the plates
was used for the luciferase assay and the other for the
cytotoxicity assay. For delivery by cationic lipid mixture of
1 mM oligonucleotides or conjugates and 10 mlm l
 1 of
Lipofectamine2000 in Opti-MEM (both Invitrogen) serum-
free medium were prepared according to manufacturer’s
manual. After 20 min at room temperature, subsequent dilu-
tions were prepared from oligonucleotide/Lipofectamine2000
mixture. Cells were incubated with oligonucleotide/Lipofec-
tamine2000 mixtures for 3 h, washed with phosphate-buffered
saline (PBS) and left for additional incubation in DMEM/10%
FBS for 18 h. For free conjugate delivery, conjugates were
prepared at 2.5 mM concentration in Opti-MEM, subsequently
diluted and added to the cells for 6 or 24 h incubation followed
by 18 h incubation in DMEM/10% FBS.
Luciferase assay: Cell lysates were prepared and analysed
using the Dual Luciferase Reporter Assay System (Promega)
and relative light units for both ﬁreﬂy and Renilla luciferase
read sequentially using a Berthold Detection Systems Orion
Microplate luminometer. Each data point was averaged over
two replicates of three separate experiments.
Toxicity assay: The extent of toxicity was determined by
measurement of the proportion of live cells colorimetrically
using CellTiter 96 AQueous One Solution Assay (Promega).
The absorbance at 490 nm was read usinga Molecular Devices
Emax microplate Reader. Each data point was averaged over
two replicates of three separate experiments.
The luciferases’ activities results were normalized to the
absorbance data from the toxicity assay, which reﬂects the
amount of live cells.
Confocal microscopy
HeLa cells or human ﬁbroblasts (15 · 10
3 cells) were plated
on 8-well Lab-Tek chambered coverglass (Fisher Scientiﬁc)
in DMEM/10%FBS and cultured overnight. The medium
was discarded and cells were washed with PBS followed
by incubation with 300 ml of 0.5 mM oligonucleotide/
Lipofectamine2000 complex in OptiMEM for 3 h, free
Figure 1. Scheme for formation of disulphide-linked conjugates of cysteine-containing peptides with 50-thiol-substituted oligonucleotides and sequences of the
oligonucleotides A, B and C. Reagents: (i) DTT, 0.1 M TEAA and (ii) dipyridyl disulphide, 0.1 M TEAA.
30 Nucleic Acids Research, 2005, Vol. 33, No. 12.5 mM conjugates or conjugate/peptide mixtures in OptiMEM
for 5 or 24 h. The conjugate/peptide mixtures were sonicated
for 1 min prior to addition to the cells. For nuclear staining,
cells were washed three times with PBS before addition of
300 ml OptiMEM containing Hydroethidine (20 mg/ml) and
incubated for 1 h at 37 C. After two washes, 300 ml of Opti-
MEM (without phenol red) (Invitrogen) medium containing
HEPES buffer was added into the wells for observation of
living cells.
The cells were observed with a Radiance 2100 confocal
system on a Nikon Eclipse TE300 inverted microscope
using a 60· Planapo objective N.A. 1.4. A 488 nm Argon-
laserline was used to excite ﬂuorescein and a HQ 515/30
emission ﬁlter was used for observation of the green emission.
Hydroethidine was excited with a 543 nm (green) HeNe-laser
anddetectedusingaHQ570LP(orange)emissionﬁlter.Adual
ﬂuorescence method was used with a Differential Interference
Contrast (DIC) transmission channel. The images in the three
channels were acquired sequentially at  1 frame per second
with a scanning resolution of 512 · 512 pixels and a Kalman
average of 6 frames was used. When comparing the uptake or
activity of the oligonucleotides, the imaging conditions (such
as photomultiplier gain/offset, laser intensities and confocal
aperture size) were kept constant for the observation of the
different oligos, so that the intensities represent the true
differences in uptake/activity.
Quantitation of fluorescence in cells
A 96-well plate containing HeLa cells was prepared as
described above and cells were transfected either with carbox-
yﬂuorescein-labelled oligonucleotide–peptide conjugate for
5 h prepared as for microscopy or for 3 h with 0.5 mM oligo-
nucleotides complexed with transfection reagent as above.
Cells were washed twice with PBS and lysed for 20 min
with 20 ml of passive lysis buffer (Promega), which is the
same as used in the Dual Luciferase Reporter Assay System.
After 5 min centrifugation at 2500 g, the cell lysate was trans-
ferred to a 96-well assay plate. The cell debris were washed
with 100 ml of water, and after centrifugation the supernatant
was added to the cell lysate followed by ﬂuorescence meas-
urement. The ﬂuorescence of conjugates or oligonucleotides
was detected using a microplate ﬂuorimeter (Fluoroskan, Lab-
systems) supplied with a 460/536 nm excitation/emission ﬁlter
pair. The resulting ﬂuorescence was normalized to the back-
ground amount of ﬂuorescence of untreated cells and
expressed as the percentage of added cellular ﬂuorescence
over background. Each data point was averaged over two
replicates of three separate experiments.
RESULTS
Synthesis of disulphide conjugates of oligonucleotides
with CPPs
The ﬁrst published method of disulphide-bond formation
involved reaction of a thiol-modiﬁed oligonucleotide with a
3-nitropyridinesulphenyl (Npys) activatedN-terminalcysteine
residue of an NLS peptide (35). Subsequently, the most reli-
able method seems to be pyridyl sulphide (Pys) activation of
the peptide and reaction with the oligonucleotide (Figure 1,
Route A) or activation of a thiol-modiﬁed oligonucleotide
with 2,20-dipyridyldisulphide and reaction with a cysteine-
containing peptide (Route B) (23,25,36–38). Simple peptide
conjugates of oligonucleotides can be prepared in high yield
and puriﬁed by RP–HPLC (30). However, cationic peptides
(including many well-known CPPs) associate with negatively
charged phosphodiester or phosphorothioate oligonucleotides
and cause precipitation, especially when excess peptide isused
to drive the reaction to completion (25,38,39). To overcome
this problem, Viv e es and Lebleu reported that a Tat peptide
could be coupled to a deoxyoligonucleotide in the presence
of 0.4 M potassium chloride solution and 40% acetonitrile
to maintain solubility (38). For hydrophobic peptides,
Antopolosky et al. (25) suggested coupling in the presence
of 90% formamide. We have investigated the latter denaturing
agent for conjugation of CPPs to oligonucleotides.
In Route A, peptides with N-terminal cysteine were pre-
pared on solid-phase either to carry a Npys group on the side-
chain of the cysteine or synthesized as the free peptide and the
cysteine residue activated post-assembly by reaction with 2,20-
dipyridyldisulphide to form the Pys derivative and then puri-
ﬁed by HPLC. C-terminal cysteine-containing peptides were
all activated to form the Pys derivative before conjugation. An
advantage of Route A is that the component that is prepared on
smaller scale (the oligonucleotide) requires less manipulation
prior to conjugation. Conjugations were carried out in 70%
formamide with a TEAA buffer and with 4-fold excess peptide
component for 15–30 min. In some cases, Route B was used.
Here a smaller excess of peptide was required (2.5-fold) over
oligonucleotide, and there was generally a slightly better con-
version into conjugate. This may be due in Route A to traces of
reducing agent DTT remaining in the oligonucleotide com-
ponent before conjugation, whereas in Route B the oligonu-
cleotide component is activated with 2,20-dipyridyldisulphide.
The disadvantage is that the oligonucleotide component must
be puriﬁed again by HPLC after activation, resulting in some
losses. Thus, there is little to choose between the two routes
and the product is identical in each case.
Our ﬁrst targets were disulphide conjugates of several well-
known CPPs [Tat (48–58) (40), Penetratin (21), the homo-
peptide R9 (41), R9F2 (42) and Transportan (26)]. Tat was
coupled with a 12mer OMe (oligo A) to give conjugates
1 and 2 (Table 1). All 5 CPPs were conjugated with a 12mer
Table 1. List of conjugates synthesized
Peptide Conjugate-
Oligo A
Conjugate-
Oligo B
Conjugate-
Oligo C
C-Tat-NH2 13
Tat-C-NH2 24 9
C-Penetratin-NH2 5
Penetratin-C-NH2 61 0
CR9-OH 7
R9C-OH 8 11
R9F2C-NH2 12
C-Transportan-NH2 13
C-R4-Tat-NH2 14
R4-Tat-C-NH2 15
C-Tat-Tat-NH2 16
Tat-Tat-C-NH2 17
K4-Tat-C-NH2 18
R6-Penetratin-C-NH2 19
The sequences of the oligonucleotides are shown in Figure 1.
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13. C-terminal Tat, Penetratin and R9 conjugates were made
with a 16mer 20-O-methylphosphorothioate (OMe/PS) oligo-
nucleotide (oligo C) to give conjugates 9–11. All three oligo-
nucleotides are complementary to the HIV-1 TAR RNA apical
loop as previously described (8,14). Each oligonucleotide was
synthesized with a 50 C6-thiol linker and a 30 6-carboxyﬂuor-
escein attachment (Figure 1). Peptides contained additionally
either an N- or C-terminal cysteine residue (for sequences, see
Materials and Methods).
Products were puriﬁed by short path ion exchange chroma-
tography (Resource Q) under highly denaturing conditions
(50% formamide) to ensure that the desired conjugate was
quickly separated from excess peptide and to prevent
precipitation. A typical HPLC chromatogram is shown in
Figure 2A, which shows that the conjugate is well resolved
and always by far the major component (conversions >90%).
The conjugate could then be recovered by dialysis and
lyophilization and generally redissolved without difﬁculty:
conjugates 1–9, 12 and 13 in water, conjugates 10 and 11
in low strength buffer (0.01 M TEAA). All products showed
a single conjugate peak in the expected mass range by
MALDI-TOF mass spectrometry (Table 2 and Supplementary
Material).Innocaseusingmatrix3,inwhichbothpeptidesand
oligonucleotide–peptide conjugates can be readily observed
(see Materials and Methods), was more than a trace of peak
seen in the expected mass region of free peptide for all
conjugates prepared, which conﬁrms the homogeneity of
the products. Isolated yields of conjugates were 36–78%.
We have not had success in puriﬁcation of conjugates
from conjugation reactions by use of an alternative ion
exchange column (e.g. DNAPac PA 100) or a reversed
phase column commonly used for oligonucleotide or peptide
puriﬁcations, due to precipitation and aggregation. These
experiences are similar to those of Prater and Miller who
recently failed to obtain a conjugate of Tat peptide with
a ﬂuorescently labelled 20-O-methyl oligonucleotide after
trying several options (39). In contrast, conjugations and
Resource Q puriﬁcations in the presence of formamide as
denaturing agent in all cases were successful and therefore
can be recommended for a range of cationic or other CPPs
to oligonucleotides containing phosphodiester or phosphoro-
thioate backbones.
Binding of CPP–oligonucleotide conjugates to the
TAR target
In a previous study, we found that stably linked K-FGF and
Transportan-TP10 conjugates of OMe/LNA 12mer oligo B
were able to bind the TAR RNA target without loss of binding
strength (14). Since disulphide conjugates are potentially
Table 2. Properties of conjugates synthesized: retention time on RP–HPLC,
calculated and observed masses by MALDI-TOF mass spectrometry, isolated
yields and salts used for dissolution of conjugates
Conjugate Retention
time
(min)
Calculated
molecular
mass
Observed
MALDI
molecular
mass
Isolated
yield (%), salts
1 10.84 6315.22 6315.52 55, 0
2 11.13 6315.22 6312.94 49, 0
3 12.99 6316.25 6315.34 69, 0
4 13.22 6316.25 6316.07 74, 0
5 13.28 7183.31 7181.99 68, 0
6 13.87 7183.31 7183.36 75, 0
7 12.66 6247.15 6244.28 50, 0
8 12.54 6247.15 6243.30 36, 0
9 15.24 7871.20 7869.28 70, 0
10 18.45 8738.26 8730.89 63, 0.01 M TEAA
11 18.04 7802.1 7801.39 40, 0.01 M TEAA
12 12.31 6540.52 6539.62 56, 0.1 M TEAA
13 15.95 7663.92 7659.08 78, 0
14 9.80 6941.00 6936.68 24, 0.1 M TEAA
15 9.94 6941.00 6944.49 55, 0.1 M TEAA
16 8.10 7792.01 7799.79 15, 1 M TEAA,
1MN H 4Cl
17 8.02 7792.01 7788.30 12, 1 M TEAA
18 10.27 6828.94 6827.88 58, 0.1 M TEAA
19 8.85 8120.43 8161.83
(Broad
hump)
Not possible to
completely dissolve
in 2 M TEAA
Figure 2. HPLC chromatograms showing purification of conjugates. (A)
Conjugation of Penetratin-Cys with OMe/LNA oligo B activated with
Pys (Route B); peaks (i) salts and formamide, (ii) excess Penetratin-Cys
(iii) conjugate product, (iv) unconjugated oligoB (Pys). The solid trace is at
280nmandthedashedtraceisat480nm,whichidentifiesthefluoresceinlabel
on the oligonucleotide. (B) Conjugation of K4Tat-Cys(Pys) + OMe/LNA oligo
B (free SH) (Route A); peaks (i) salts and formamide, (ii) excess K4Tat-
Cys(Pys), (iii) conjugate product and (iv) unconjugated oligo B (free SH).
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transcription buffer of oligo B containing a 50-C6-thiol linker
(which would be obtained on reduction of the disulphide link-
age) to a synthetic 39mer TAR RNA. The apparent Kd was
2.2 – 0.2 nM, very similar to that of unfunctionalized oligo B
(8,14).WealsomeasuredtheapparentKdofbindingtoTARof
typical cationic CPP conjugates of oligo B Tat conjugate 4:
1.7 – 0.4 nM and oligo B Penetratin conjugate 6: 6.2 – 1.1 nM.
Thus, whether or not a CPP peptide is removed from the oligo
during passage through the cell, binding strength to the target
TAR site is unlikely to be signiﬁcantly affected by the con-
jugation chemistry. Note that in the case of the Tat peptide
conjugate, the peptide part is unlikely to compete with the
oligo B part signiﬁcantly for binding to TAR, since it was
previously reported by us that a slightly longer peptide that
includes the basic domain and the C-terminal Glu-rich region
of Tat (residues 48–72) has a much higher Kdof about 300 nM,
as judged by mobility shift analysis (43). The Kd in transcrip-
tion buffer of PS/OMe 16mer oligo C containing 50-C6-thiol
linker was found to be 8.9 – 0.8 nM, slightly weaker than that
of OMe/LNA 12mer oligo B.
Trans-activation inhibition of CPP–oligonucleotide
conjugates
We have published previously the use of a stably transformed
HeLa cell line that contains three plasmids (8,14). Tat is
produced from the ﬁrst plasmid and trans-activates the
HIV-1 LTR on a second plasmid in order to produce ﬁreﬂy
luciferase. The third plasmid produces the control Renilla
luciferase under constitutive CMV promoter regulation.
Speciﬁc knockdown of ﬁreﬂy luciferase expression, but not
Renilla luciferase, can be obtained only if the oligonucleotide
is taken up by a large majority of cells and is able to inhibit the
HIV LTR by sterically blocking the TAR RNA target over
the assay period. Thus, this assay system measures both the
cellular activity of the oligonucleotide or its conjugate as well
as its cell delivery ability. We showed previously speciﬁc
inhibition of Tat-dependent trans-activation by a 12mer OMe/
LNA mixmer (oligo B), when delivered by cationic lipids,
but not mismatched or scrambled oligomers (8) and carried
out a range of structure–activity studies (14). In contrast, OMe
12mer (oligo A) was entirely inactive in this cell assay.
Activity of conjugates by free uptake. We tested all the CPP
conjugates of the OMe/LNA mixmer oligo B (conjugates 3–8,
12 and 13) in the cell assay by free uptake. None of these
conjugates showed inhibition of ﬁreﬂy luciferase (Tat-depend-
ent trans-activation) or control Renilla Luciferase up to
2.5 mM concentration tested (Figure 3A and B, left and centre
panels, which shows two representative examples of Tat and
Penetratin conjugates 4 and 6). In order to simulate as closely
as possible the conjugates of Astriab-Fisher et al. (24), we also
tested in our assay system Tat, Penetratin and R9 conjugates of
a 16mer OMe/PS oligonucleotide targeted to TAR (oligo C,
conjugates 9–11). No activity was observed up to 2.5 mM for
all three conjugates (data not shown).
Activity of oligos B and C and their conjugates by cationic
lipid delivery. OMe/LNA 12mer (oligo B), either without
or with the 50-thiol linker, when delivered by cationic lipid
Lipofectamine2000 showed dose-dependent inhibition of
ﬁreﬂy luciferase expression but not Renilla luciferase expres-
sion (Figure 3C and D). This is in line with our previous
ﬁndings for delivery of the same oligonucleotide with another
cationic lipid as well as a cationic surfactant (8,14). A 16mer
OMe/PS oligo C that contains a 50-thiol linker did not show
dose-dependent inhibition of ﬁreﬂy luciferase or Renilla luci-
ferase, whereas the same oligo B containing the 50-DMT-C6-
S-S-linker before treatment with reducing agent (50-thiol
capped)withdeliverybyLipofectamine2000showedselective
inhibition of ﬁreﬂy luciferase in the HeLa cell assay (Figure
3C and D). Thus oligo C in principle does have target-speciﬁc
activity when delivered by cationic lipid, but we have no
explanation for the lack of activity of the 50-thiol oligo C.
In general, we found that CPP–oligo B conjugates showed
speciﬁc ﬁreﬂy luciferase inhibition activity in the HeLa cell
assay in the presence of cationic lipid, but at varying levels.
For example, conjugate 6 (OMe/LNA oligo B conjugated to
Penetratin) showed a moderately good dose-dependent reduc-
tion inﬁreﬂyluciferase activity withoutconcomitantreduction
in Renilla luciferase activity (Figure 3A and B, right panels).
Similar results were seen for the Tat conjugate 4 but the
Transportan conjugate 13 showed both ﬁreﬂy and Renilla
luciferase inhibition (data not shown). The varying levels of
activity may reﬂect varying abilities of the conjugates to be
packaged by cationic lipid, depending on the particular
attached peptide.
Cell penetration of CPP–oligonucleotide conjugates
Since the CPP–conjugates failed to show signiﬁcant cellular
activity by free delivery, we asked whether 30-carboxyﬂuor-
escein labelled CPP–oligonucleotide conjugates could penet-
rate HeLa cells and where they might be localized. We
therefore incubated them at 2.5 mM concentration with HeLa
cells for 5 h, and observed the uptake by confocal microscopy
(Figure 4). The 30-ﬂuorescent label allows any oligonucleotide
component that has been taken up by cells to be seen as a green
ﬂuorescence.Inaddition,ahydroethidinedyewasusedtostain
the cell nucleus. Not only does this make it easier to observe
nuclear uptake (as a green or yellow colour), but also only the
nuclei of live cells are stained red, ensuring that only healthy
cells are included in observations.
Free uptake of CPP–oligonucleotide conjugates. In the
absence of cationic lipid, unconjugated oligos A, B and C
do not enter HeLa cells [(14) and data not shown]. Conjugates
1 and 2 (OMe oligo conjugates) and conjugate 3 (OMe/LNA
oligo conjugated with the N-terminus of Tat peptide) showed
only a very weak ﬂuorescence (data not shown). In contrast,
conjugate 4 (OMe/LNA oligo-conjugated with the C-terminus
of Tat peptide) showed a little more noticeable internalization
for most cells (Figure 4A). Fluorescence was not seen in the
nucleus, but in vesicular compartments within the cytosol.
Very similar uptake patterns were observed for conjugate 6
(OMe/LNA oligo conjugated with the C-terminus of Penetra-
tin peptide) (Figure 4B) but only very weakly for conjugate 5
(OMe/LNA oligo conjugated with the N-terminus of Penetra-
tin peptide) (Figure 4C). Neither conjugates 7 or 8 (containing
R9 in different orientations) showed signiﬁcant cell uptake
(data not shown). However, the conjugate of OMe/LNA
oligo B with R9F2 (conjugate 12) showed substantial cellular
ﬂuorescence, once again conﬁned to vesicular compartments
Nucleic Acids Research, 2005, Vol. 33, No. 1 33(Figure 4D). Thus, unlike R9, the CPPs Tat, Penetratin and
R9F2 do enhance free HeLa cell uptake of oligo B somewhat
when conjugated at the C-terminus, but no evidence of release
was seen from endosomal compartments. No signiﬁcant
improvement in uptake for any of these conjugates was
seen after 24 h incubation nor was any nuclear ﬂuorescence
seen (data not shown).
We reported previously that 30 ﬂuorescently labelled OMe/
LNA oligo B conjugated stably with Transportan-TP10
showed only weak cytosolic uptake in HeLa cells (14). Simi-
larly, the uptake of oligo B disulphide linked to full-length
Transportan (conjugate 13) was extremely weak (data not
shown).
The C-terminal Penetratin conjugate of PS/OMe oligo C
(conjugate 10) showed a very similar level of uptake into
vesicular compartments (Figure 4E) as for the same conjugate
of oligo B (Figure 4B). Once again no nuclear uptake was
seen, in contrast to the recent report of Astriab-Fisher et al.
(24) for a very similar disulphide Penetratin-PS/OMe oligo-
nucleotide. Conjugates of Tat (conjugate 9) and R9 (conjugate
11) showed only very weak uptake into the cytosol (data not
shown).
Synthesis and activity of conjugates of OMe/LNA
oligo B with CPPs containing additional
cationic charge
Since the formal charge balance of conjugates 1–12 remains
negative overall, we wondered whether addition of further
cationic charge to the CPP Tat or Penetratin could improve
the level of uptake into HeLa cells and/or aid release from
endosomes. Hence, we synthesized a number of Tat and Pene-
tratin peptides having additional Arg or Lys residue extensions
as well as containing N- or C-terminal Cys residues and con-
jugated these to OMe/LNA Oligo B (Table 1). Conjugates
14 and 15 contained Tat with 4 additional Arg residues in
different orientations, 16 and 17 contained double Tat peptides
in different orientations, 18 contained Tat and 4 additional Lys
residues on the N-terminus and a C-terminal Cys, and 19
contained Penetratin with 6 additional Arg residues on the
N-terminus and a C-terminal Cys. These conjugation reactions
were in general more difﬁcult to carry out due to precipitation
which almost always occurred, requiring the addition of extra
TEAA buffer and formamide to maintain solubility. However,
puriﬁcations of the conjugates by HPLC were readily achieved
Figure 3. Inhibitory effects of oligonucleotides and conjugates in the HeLa cell reporter assay. (A and C) Firefly luciferase activity. (B and D): Control Renilla
luciferaseactivity.AandBpanels,leftsections:freedeliveryofconjugate4;centresections:freedeliveryofconjugate6;rightsections:Lipofectamine2000delivery
of conjugate 6. (C and D) Lipofectamine 2000 delivery from left to right: oligo B without linker, oligo B with 50-thiol, oligo B with 50-capped thiol, oligo C with
50-thiol and oligo C with 50-capped thiol.
34 Nucleic Acids Research, 2005, Vol. 33, No. 1Figure4. Confocalmicroscopeimagesof the freeuptakeoffluorescein-labelled CPPconjugates (green)into HeLacells.Left panelsshow a rangeof cells (nucleus
stainedred).CentralpanelsarethesamecellsinDIC.Rightpanelsshowamagnificationofasinglecellboxedintheleftpanels.Horizontally,(A)conjugate4(OMe/
LNAoligoconjugatedwiththeC-terminusofTatpeptide),(B)conjugate6(OMe/LNAoligoBconjugatedwiththeC-terminusofPenetratin),(C)conjugate5(OMe/
LNA oligo B conjugated with the N-terminus of Penetratin), (D) conjugate 12 (OMe/LNA oligo B conjugated with R9F2) and (E) conjugate 10 (PS/OMe oligo C
conjugated with the C-terminus of Penetratin).
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Lower isolation yields were obtained (12–55%) due to tend-
encies of the conjugates to precipitate during dialysis or to
be partially insoluble after lyophilization. In all cases, a high
salt buffer was necessary for dissolution (1 M TEAA – 1M
ammonium chloride solution). Conjugate 19 could not be fully
dissolved in any aqueous buffer. Products were characterized
by MALDI-TOF mass spectrometry and in all cases showed
within experimental error the expected mass values (Table 2).
None of these conjugates showed signiﬁcant inhibition of
trans-activation (ﬁreﬂy luciferase expression) in the HeLa
cell assay under free delivery for 5 h (data not shown).
When viewed by confocal microscopy, OMe/LNA oligo B
conjugates 15 (R4-Tat), 17 (Tat-Tat) and 18 (K4-Tat) all
showed substantial cytosolic uptake into vesicular structures
(Figure 5A–C). The uptake levels appeared to be generally
stronger for these more cationic conjugates than for those with
a CPP alone, but still less than that for cationic lipid delivery
Figure5.Confocalmicroscopeimagesofthefreeuptakeoffluorescein-labelledCPPconjugatescontainingadditionalcationiccharge(green)intoHeLacells(nuclei
stainedred).VerticalPanelsasinFigure4legend.Horizontally,(A)Conjugate15(OMe/LNAoligoBconjugatedwithR4-Tat),(B)Conjugate17(OMe/LNAoligoB
conjugated with Tat-Tat), (C) Conjugate 18 (OMe/LNA oligo B conjugated with K4-Tat) and (D) Conjugate 18 (OMe/LNA oligo B conjugated with K4-Tat), 24 h
experiment.
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uptake in any case. After 24 h incubations, some further cyto-
solic uptake was seen for the K4-Tat conjugate 18 (Figure 5D)
and for the R4-Tat conjugate 15 but no nuclear uptake nor
trans-activation inhibition activity was seen in the HeLa cell
assay (data not shown).
Uptake of conjugates in human fibroblasts
We asked whether the restriction of uptake of CPP conjugates
of oligonucleotides into cytosolic vesicles is a feature only
of HeLa cells or whether this also extends to other cell
lines. We therefore incubated cultured human foreskin ﬁbro-
blasts (44) with certain ﬂuorescein-labelled conjugates that
showed good uptake into HeLa cells. For example, the
Penetratin–C-terminal conjugate 6 showed a very similar
cytosolic uptake to that seen in HeLa cells except that there
was a more deﬁned punctate nature of the ﬂuorescence and a
more even distribution through the cytosol (Figure 6A). No
nuclear uptake was observed. Interestingly, the difference in
uptake levels for the C-terminally linked conjugates of Tat
and Penetratin conjugates 4 and 6, and N-terminally linked
conjugates 3 and 5 were less pronounced than for HeLa cells
(data not shown). A strong cytosolic pattern of uptake was also
observed for the R9F2 conjugate 12 (Figure 6B) and for the
R4-Tat conjugate 15 (Figure 6D), but uptake of R9 conjugates
7 and 8 was very weak (data not shown). The uptake level
of Transportan conjugate 13 into ﬁbroblasts was much
better than that into HeLa cells (Figure 6C). In addition
to the punctate cytosolic distribution, there was more
membrane association seen, which may reﬂect the greater
hydrophobicity of the Transportan peptide. Nevertheless,
there was still no nuclear uptake observed in any case.
No further improvements in uptake were seen for 24 h incuba-
tion (data not shown). Thus in general, uptake of conjugates
into human ﬁbroblast cells was not dissimilar to that of
HeLa cells.
Uptake of CPP–oligo conjugates into HeLa cells
in the presence of additional free CPP
The above activity and cellular uptake results contrast with
some previous reports of antisense or steric block activity and
nuclear delivery of Penetratin and Tat conjugates of oligo-
nucleotides (21–24). Noting the tendency of CPP conjugates
to aggregate or precipitate in conjugation reactions, we took
considerable care in isolation and puriﬁcation of conjugates to
remove excess CPP peptide. Therefore, we questioned
whether uptake of conjugates into HeLa cells could be inﬂu-
enced by addition of further equivalents of unconjugated CPP.
Addition of half, one or two molar equivalents of Tat peptide
to 2.5 mM conjugate 4 (Tat C-terminally conjugated to OMe/
LNA oligo B) resulted in each case in substantially increased
uptakeasobservedbyconfocalmicroscopy(Figure7panelA).
Extraction and measurement of the ﬂuorescence showed
that the ﬂuorescence was enhanced  190% in the case of
2 equivalents of Tat (Figure 8). The effect was even more
dramatic with Penetratin addition to conjugate 6 (Penetratin
C-terminally conjugated to OMe/LNA oligo B) with a 440%
enhancement of uptake (Figure 7 panel B and Figure 8). The
amount of ﬂuorescence internalized in the latter case was
substantially more as compared to that delivered by 0.5 mM
oligo B using Effectin 12 cationic lipid for 3 h which was
enhanced 80% (Figure 8). When 2 equivalents of Tat or
Penetratin were added to unconjugated oligo B alone, the
improvement in uptake, 110% and 56%, respectively, was
less than that for the conjugates (Figure 8). However, in no
case did we observe signiﬁcant nuclear ﬂuorescence using
the HeLa cell line. The results show that free CPPs Tat
and Penetratin act to help substantially the conjugates to
enhance entry into the cell, presumably through complexa-
tion, but that they do not help release from the endosomal
compartments.
Figure 6. Confocal microscope images of the free uptake of fluorescein-
labelled CPP conjugates (green) into human fibroblasts (nucleus stained
red). Left panels show a range of cells (nucleus stained red). Right panels
are the same cells in DIC. Horizontally, (A) conjugate 6 (OMe/LNA oligo
B conjugated with the C-terminus of Penetratin), (B) conjugate 12 (OMe/
LNA oligo B conjugated with R9F2), (C) conjugate 13 (OMe/LNA oligo B
conjugated with Transportan) and (D) conjugate 15 (OMe/LNA oligo B
conjugated with R4-Tat).
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Synthesis and cell uptake of peptide–oligonucleotide
conjugates
Hitherto, the synthesis of conjugates of oligonucleotides with
highly cationic cell-penetrating peptides has been extremely
hard. A key area of concern has been the homogeneity of the
conjugate product. This is particularly the case for cationic
CPPs when conjugation is carried out by fragment coupling
and where typically excess peptide is added to the oligo-
nucleotide.Weandothers(38,39)haveobservedhowaggrega-
tion and precipitation can occur during conjugation reactions
and puriﬁcations under non-denaturing conditions, presum-
ably as a result of tight binding of excess cationic peptide
to the conjugate and starting oligonucleotide. We have now
developed rapid and reliable methods of disulphide conjuga-
tion of oligonucleotides to cationic and other CPP peptides,
and short path anion exchange chromatography puriﬁcation
under highly denaturing conditions to ensure that signiﬁcant
excess cationic peptide does not remain bound to the conjug-
ate. The principles should also be applicable to other chemis-
tries of conjugation that tolerate denaturing agents. These
methods allow for the ﬁrst time a more systematic investiga-
tion of cell uptake of CPP–oligonucleotide conjugates.
We have shown here that in many cases, CPP
conjugation does indeed enhance free uptake of OMe/LNA
oligonucleotides into HeLa cells and human ﬁbroblasts in
culture, but that the level of uptake does not approach the
level that can be achieved with cationic lipid delivery. The
addition ofextra cationic charge toTat peptide,oradouble Tat
peptide, enhances uptake further beyond that of Tat alone, but
this is at the cost of increased difﬁculties in puriﬁcation,
isolation and solubility of the conjugate. In contrast, a dra-
matic effect in enhancement of uptake into HeLa cells was
observed when extra equivalents of cationic CPPs Tat or
Penetratin were added to puriﬁed oligonucleotide–CPP con-
jugates (Figures 7 and 8). This points to a signiﬁcant delivery
role that Tat and Penetratin have on the conjugates, presum-
ably by complexing the conjugate to shield better the negative
charges. The delivery was greater for conjugates than that seen
for complexation of free oligonucleotide. These results high-
light concerns about cell uptake results from a number of
previous cationic peptide conjugate studies of oligonucleo-
tides or siRNA where a strong denaturing agent has not
been used during synthesis and puriﬁcation (21,22,45–48).
The mechanism of CPP-directed cell delivery
The mechanism of CPP-directed cell uptake has been contro-
versial for some time. Initially, it was thought that such
peptides translocate across cell membranes in an energy-
independent way that avoids the endosomal uptake pathways
Figure7.Confocalmicroscopeimagesofthefreeuptakeoffluorescein-labelledCPPconjugates(green)intoHeLacells(nucleistainedred).(A)Effectofadditional
equivalentsofTatpeptideonuptakeof2.5mMTat-Cys-OligoB, 5h.(B)Effectofadditionalequivalents ofPenetratinpeptideonuptakeof2.5mMPenetratin-Cys-
Oligo B, 5 h. (C) Lipofectamine 2000 delivery of 0.5 mM oligo B, 3 h. Note here the nuclear localization seen (white arrows) in addition to cytosolic uptake.
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re-evaluated following the realization that the use of cell ﬁxa-
tion agents, such as methanol or formaldehyde, can give rise to
artefacts during confocal microscopy and that only data from
unﬁxed cells may be reliable. Thus, ﬂuorescein-labelled Tat
peptide was found to enter HeLa cells by an endosomal path-
way and was found in cytosolic vesicles (50). Similarly studies
of TAMRA-labelled R9 into live CHO-K1 cells have con-
ﬁrmed that this peptide also enters via endocytosis, and is
seen only in cytosolic vesicles and not the nucleus (51).
Our own data for Tat (48–58), Penetratin and R9F2 peptides
ﬂuorescein-labelled on a C-terminal cysteine residue have
shown in all cases delivery entirely into cytosolic compart-
mentsin HeLa cells (Arzumanov, A., Turner, J. and Gait,M.J.,
unpublished data). By contrast, a recent report showed that
TAMRA-labelled Tat peptide was taken up by HeLa cells and
located predominantly in nuclear bodies thought to be the
nucleolus (48) and nuclear localization was also reported
recently for live HeLa cell delivery of C-terminally FITC-
labelled Tatpeptide(52).Recent re-evaluationofﬂuorescently
labelled Penetratin uptake showed endosomal uptake, but
some polyarginine analogues (such as R7W) have shown evid-
ence of energy-independent uptake (53). Thus for CPPs alone,
there remains conﬂicting data about uptake and localization.
Antopolsky et al. reported that disulphide conjugates of
hydrophobic peptides and phosphorothioate oligonucleotides
were taken up and localized in endosomal compartments, and
they also reported that the disulphide bond appeared to be
intact after isolation of such conjugates from cells after several
hours (25). Ours is the ﬁrst detailed study aimed at correlation
of nuclear steric block activity with cell uptake for a range of
conjugates of cationic and other well-known CPPs to OMe/
LNA phosphodiester and phosphorothioate oligonucleotides.
In no case of free uptake of conjugates into HeLa cells did we
see nuclear localization. Instead all the ﬂuorescence was found
within cytosolic compartments. This explains why with free
conjugate delivery, we did not observe signiﬁcant reduction in
ﬁreﬂy luciferase expression resultant from inhibition of Tat-
dependent trans-activation. In contrast, our main test OMe/
LNA 12mer oligonucleotide B is active when delivered by
cationic lipids, with or without a 50-thiol linker. A free 50-thiol
would be obtained if the disulphide bond is cleaved during cell
uptake, but this seems unlikely given the results of Antopolsky
et al. (25). CPP–oligo B conjugates were also found to be
active when delivered by cationic lipids, but with variable
efﬁciency, presumably due to lipid packaging variations.
Our results showing only cytosolic localization in both
HeLa cells and human ﬁbroblasts for our complete range
of conjugates is consistent with recently reported studies
of a C-terminal linked Tat conjugate of a molecular beacon
phosphodiester oligonucleotide where the linkage (thiol–
maleimide or disulphide) is through a base residue. Uptake
Figure 8. Quantitation of internalized fluorescence. Percentage increase in cellular fluorescence over background levels for (left to right) addition of Tat peptide to
2.5 mM conjugate 4, addition of Penetratin peptide to 2.5 mM conjugate 6, compared to 2.5 mM Oligo B alone, 2.5 mM Oligo B with 2 equivalents of Tat peptide or
2 equivalents of Penetratin peptide and 0.5 mM oligo B with transfection agent Lipofectamine 2000.
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ﬂuorescent signal, presumably, due to opening of the beacon
upon hybridization with GAPDH mRNA, was seen in cyto-
solic compartments within 30–60 min (46). No ﬂuorescent
signal was seen in the cell nucleus. Interestingly, a sequence-
speciﬁc molecular beacon signal was only seen with peptide
delivery and not with cationic lipid delivery, suggesting that
localization may not be to the same endosomal compartments
in the two cases.
It is believed that there are several endosomal portals in
mammalian cells, for example clathrin-dependent and
cavaeloae-dependentendocytosis,aswell asmacropinocytosis
[reviewed in (54)]. Although the particular portal or portals
used by CPPs or CPP–protein conjugates are now being
studied [e.g. (51,55,56)], this has yet to be established for
oligonucleotide–peptide conjugates. Further, there is only
limited knowledge offactorsaffecting release fromendosomal
compartments (or leakage) into the cytosol. Once in the cyto-
sol, short oligonucleotides are known to track readily into the
nucleus by passive diffusion across the nuclear membrane
(57). It is clear that endosomal release of peptide conjugates
of oligonucleotides is inefﬁcient in both HeLa cells and human
ﬁbroblasts. Therefore, at least with the current list of well-
known CPPs, peptide conjugation is unlikely to be a panacea
for the nuclear delivery of anionic oligonucleotides unless we
can ﬁnd better sequences that can cause sufﬁcient endosomal
membrane disruption. However, some cell lines of different
lineage may have less demanding endosomal release charac-
teristics, e.g. Jurkat T cells (58).
We are unable to reconcile our results fully with the studyof
Astriab-Fisher et al. who prepared disulphide conjugates of a
30-TAMRA-20-O-methylphosphorothioate oligonucleotides to
Tat or Penetratin (24). In this study, denaturing agents were
used both in the conjugations and in puriﬁcations. These con-
jugates were reported to localize both in endosomal com-
partments and strongly in the nucleus of HeLa 705 cells.
There was no indication of the use of cell ﬁxation during
confocal microscopy. Up-regulation of luciferase expression
was seen due to altered splicing, but the authors conceded that
the assay used was extremely sensitive and that ‘maximal
effects attained with the conjugates were several-fold less’
than for cationic lipid delivery of similar amounts of the
same oligonucleotide. In contrast, in our trans-activation
assay, the Tat-dependent HIV-1 promoter driving production
of ﬁreﬂy luciferase is very strong, and inhibition of expres-
sion will only be seen if there is signiﬁcant nuclear delivery
into most cells. Thus, weak nuclear delivery would be insuf-
ﬁcient to see activity in our robust assay.
Role of charge and hydrophobicity in cell uptake
It is interesting to note that the cationic charge of the peptide is
not the only factor mediating cell uptake, since neither of the
R9-conjugates of oligo B showed signiﬁcant uptake into HeLa
cells whereas R9F2, Tat and Penetratin did. This result is
in contrast to a recent report for good cytosolic internalization
of a disulphide-linked, FITC-labelled R9-conjugate of an
unmodiﬁed phosphodiester oligonucleotide into HepG-2
cells (45). Our results point instead to the importance beyond
cationic charge for additional residues within the peptide that
act either to space the cationic charge more amphipathically or
perhaps to add some hydrophobic character to enhance mem-
brane crossing. Combinations of hydrophobic and cationic
residues are well known for peptides used as complexing
agents for the delivery of nucleic acids (59,60). Note also
in this context that a stearylated Tat peptide has been
shown to signiﬁcantly enhance transfection of DNA into
COS-7 cells (61), and that myristoylation of polyarginine pep-
tides resulted in enhanced uptake of the peptide into HeLa
cells (52). For our conjugates, the interplay of cationic charge
and hydrophobic components of the peptide together with the
anionic charge and hydrophobic characteristics (e.g. LNA) of
the oligonucleotide cargo in cell uptake is clearly complex and
will require further investigation. Although 30-ﬂuorescein
oligo B is not taken up by HeLa cells (data not shown), we
cannot rule out the possibility that the ﬂuorescein label itself
inﬂuences the free cell uptake of the CPP conjugates.
This studyhas focussed entirely on anionic oligonucleotides
and their cell delivery and activity. Peptide conjugates of
electrically neutral peptide nucleic acids and morpholino oli-
gonucleotides have been studied recently for cellular uptake
and biological activity (62–65). A disulphide-linked Transpor-
tan conjugate of a 16mer PNA targeted to the TAR apical
stem–loop was found to inhibit Tat-dependent activity in
the 1–5 mM range in a transient luciferase reporter assay in
CEM and Jurkat cells, as well as inhibition of HIV-1 produc-
tion in chronically infected H9 cells in the same concentration
range (20). Our own results for PNA–peptide conjugates
against the TAR target will be reported shortly, but our pre-
liminary ﬁndings [as well as that of others (64)] indicate that
difﬁculties in endosomal release in HeLa cells extends also to
these conjugates (Arzumanov, A., Turner, J., Verbeure, B.,
Williams, D. and Gait, M.J., unpublished data).
In conclusion, we have made signiﬁcant improvements to
the synthesis of peptide–oligonucleotide conjugates that are
disulphide-linked to ensure high purity and shown that CPP
conjugation enhances uptake into HeLa and human ﬁbroblast
cells,but that further complexation with additional equivalents
of peptide results in substantial uptake enhancement. How-
ever, such conjugates are not released from endosomal com-
partments in HeLa cells and do not allow the oligonucleotide
to inhibitTat-dependent trans-activation that must occur in the
cell nucleus. These results provide important information
towards a better understanding of oligonucleotide cell delivery
potential.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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